Please read Dana-Farber's latest Dec 2023 Press Release. They now state that if you have a Complete or even a Very Good Response, it's Safer to Keep the SCT In Reserve due to the risk of more frequent Infections of a more Serious Nature, due to the long term damage to the Immune System.

For those that Don't Respond or Relapse Immediately or Frequently, the SCT and often Dual SCTs can be Life Saving, though newer treatment options like Car-T and BiSpecifics are showing excellent results.

Dr Costa's Masters Trial has proven that even for 1 and 2 High Risks, if you get to MRD Negative (10 -6 = none per million cells tested), it's just as durable, even now, as he's looked back after many years of follow-up on his Trial's Participants.

My Induction of DarzFasPro + RVd resulted in getting me to MRD Negative, without a SCT and without collecting my Stem Cells (Dr Berenson suggests Collection, due to the chemicals involved may damage the Marrow Microbiome). I remain on No MM Meds with Monthly Labs Monitoring and Quarterly blood sample clonoSEQ testing - as long as I'm Negative at 10 -6, my Onc is fine with Monitoring Only.

For myself, based on my very extensive research, my Plant Based Diet and the knowledge that my Natural Killer Cells are at 17% (a very healthy level), I'll never consider or need a SCT and most likely will never have to deal with MM again. In 2021, I was Stage 2, IgA Kappa, 5.2 MSpike, high risk t4;14, 80-90% bad plasma. If I ever become Positive, I know that a short term treatment cycle, not to exceed 3 months will easily resolve anything that might occur, such as the Bone Lesion in Sept. 2023 (killed off in under two weeks and back to MRD Negative in 6 weeks - simply the time for our peripheral blood to cycle to New when there's no active Cancer).

https://www.dana-farber.org/newsroom/news-relea...

DETERMINATION trial subgroup analysis suggests potential strategies for individualization of myeloma treatment | Dana-Farber Cancer Institute

https://www.dana-farber.org/newsroom/news-releases/2023/determination-trial-subgroup-analysis-suggests-potential-strategies-for-individualization-of-myeloma-treatment?fbclid=IwAR1O9EL5Y-oBqFNbxPMwY5ydqto3LPoIyX43z38IOrwRxnmlcPwsdNCt2K8_aem_AdwCjkS6o0bjadRgISoZ_sI3X_2CQM779fPYmZ_6mGMhhZDR4OuhDQU-nYt9OegpGHpm_TWAud1wXvKqqJMnfHnX